Neurol. praxi. 2017;18(3):212-215

Botulinumtoxinum A: pharmacological prerequisites for therapeutic effect

MUDr. Jiří Slíva, Ph.D.
Ústav farmakologie 3. LF UK, Praha

Botulinumtoxin is one of the most poisonous neurotoxin produced by the bacterium Clostridium botulinum. This paper deals with

the basic mechanism of action in the context of its potential for therapeutic use in muscle spasticity and other disorders. Since

today there are several medicines containing botulinumtoxin, in the text, among others, their mutual differences have been

addressed. These play an important role for different immunogenicity profiles.

Keywords: Clostridium botulinum, botulinumotoxin, spasticity, immunogenicity, neurotoxin, incobotulinumtoxin A

Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. Botulinumtoxinum A: pharmacological prerequisites for therapeutic effect. Neurol. praxi. 2017;18(3):212-215.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 2011; 305: 89-90. Go to original source... Go to PubMed...
    2. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012; 26: e1-e9. Go to original source... Go to PubMed...
    3. Blumel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations on botulinum neurotoxin A in the rabbit. Neurotox Res 2006; 9: 238.
    4. Eisele KH, Taylor HV, Blumel JJ. Immunogenicity of NT201 (Xeomin(R)) in Cynomolgus monkeys following high-dose injections. Mov Disord 2008; 23: S5.
    5. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology 1999; 53: 1850-1853. Go to original source... Go to PubMed...
    6. Frevert J. Content of botulinum neurotoxin in Botox(R)/Vistabel(R), Dysport(R)/Azzalure(R), and Xeomin(R)/Bocouture(R). Drugs R D 2010; 10: 67-73. Go to original source... Go to PubMed...
    7. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 2015; 15: 1-9. Go to original source... Go to PubMed...
    8. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010; 4: 325-332. Go to original source... Go to PubMed...
    9. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol 1997; 147: 96-102. Go to original source... Go to PubMed...
    10. Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins-a single cohort 4-year follow-up study. BMJ Open 2012; 4: pii: e000646. Go to original source... Go to PubMed...
    11. Jimenez-Shahed J. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin(R)), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatr Dis Treat 2012; 8: 13-25. Go to original source...
    12. Jost WH, Benecke R, Hauschke D, Jankovic J, Kanovsky P, Roggenkamper P, Simpson DM, Comella CL. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther 2015; 9: 1913-1926. Go to original source... Go to PubMed...
    13. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007; 67: 669-683. Go to original source... Go to PubMed...
    14. Kanovsky P, Platz T, Comes G, Grafe S, Sassin I. NT 201, botulinum neurotoxin free from complexing proteins (Xeomin(R)) provided sustained efficacy and was safe in spasticity: 89 weeks long-term data. J Neurol Sci 2009; 285: S75-S76. Go to original source...
    15. Montecucco C, Molgo J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 2005; 5: 274-279. Go to original source... Go to PubMed...
    16. Prager W. Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clin Pharmacol 2013; 5: 39-52. Go to original source...
    17. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004; 44: 167-193. Go to original source... Go to PubMed...
    18. Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez, HH. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin((R))) injections in blepharospasm. J Neural Transm (Vienna) 2013; 120: 1345-1353. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.